Bill Welch is a senior executive, business leader and entrepreneur in the precision medicine sector cutting across molecular diagnostics, genomics and targeted therapeutics. Bill’s interest and passion is in the consumerization of healthcare through precision therapeutics, genetics and digital health.
Prior to joining Illumina Ventures, Bill was CEO at Trovagene Inc., a precision oncology therapeutics and genetics company capitalizing on circulating tumor DNA in urine. Prior to Trovagene, Bill was President and Chief Executive Officer at Sequenom Inc. a leading molecular diagnostics company specializing in clinical applications of whole genomic sequencing for the reproductive health & oncology markets. While at Sequenom, Bill led the development and commercialization of first non-invasive prenatal test (NIPT) for detecting and accurately measuring fetal genomic DNA in mother’s blood and helped establish NIPT as the new global clinical standard for prenatal testing and a multibillion-dollar diagnostic market. Prior to Sequenom, Bill was Chief Commercial Officer at Monogram Biosciences, a molecular immunology and oncology technology company. Bill entered the healthcare industry with Abbott Laboratories where he held progressive management positions in licensing, technology and therapeutics. Bill serves as Board Member at Serimmune.
Bill has designed and launched products under a number of novel commercial healthcare models utilizing The Food and Drug Administration’s regulatory approvals for NDA’s, PMA's and 510 (k)'s and Center of Medical and Medicaid Services for CLIA and CAP certifications.
Bill has an MBA from Harvard University and a BS in Chemical Engineering from University of California at Berkeley.